AARTIDRUGS Q2 FY27 results at a glance
AARTI DRUGS LTD. Q2 FY27 key results metrics| Quarter | Q2 FY27 |
|---|
| Quarter ended | 30 Sept 2026 |
|---|
| Revenue | ₹826 cr |
|---|
| Revenue YoY | +26.6% |
|---|
| Operating profit | ₹116 cr |
|---|
| Operating margin | 14.1% |
|---|
| Net profit | ₹82.77 cr |
|---|
| Net profit YoY | +82.8% |
|---|
| Net profit QoQ | +65.0% |
|---|
| Net margin | 10.0% |
|---|
| Basic EPS | ₹9.07 |
|---|
| TTM revenue | ₹2,851 cr |
|---|
| TTM net profit | ₹229 cr |
|---|
| TTM net margin | 8.0% |
|---|
AARTIDRUGS Q2 FY27 results: what the numbers say
AARTI DRUGS LTD. (AARTIDRUGS) has reported its Q2 FY27 results for the quarter ended 2026-09-30. The company posted revenue of ₹826 cr and a net profit of ₹82.77 cr, translating into earnings per share of ₹9.07.
Compared with the same quarter a year earlier, revenue grew strongly by +26.6% and net profit grew sharply by +82.8%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹116 cr, an operating margin of 14.1% versus 10.4% a year ago — a gain of 3.7 percentage points.
AARTIDRUGS quarter-wise results table
Net profit
₹82.77 cr
+82.8% YoY
Operating profit
₹116 cr
+71.0% YoY
Swipe sideways to see all columns →
AARTI DRUGS LTD. (AARTIDRUGS) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q2 FY272026-09-30 | ₹826 cr | ₹116 cr | ₹82.77 cr | 14.1% | 10.0% | ₹9.07 | +82.8% | +65.0% |
| Q1 FY272026-06-30 | ₹703 cr | ₹79.74 cr | ₹50.17 cr | 11.3% | 7.1% | ₹5.49 | -6.9% | -9.1% |
| Q4 FY262026-03-31 | ₹720 cr | ₹77.76 cr | ₹55.19 cr | 10.8% | 7.7% | ₹6.05 | — | +36.1% |
| Q3 FY262025-12-31 | ₹602 cr | ₹37.09 cr | ₹40.54 cr | 6.2% | 6.7% | ₹4.44 | — | -10.5% |
| Q2 FY262025-09-30 | ₹653 cr | ₹68.03 cr | ₹45.28 cr | 10.4% | 6.9% | ₹4.95 | — | -16.0% |
| Q1 FY262025-06-30 | ₹591 cr | ₹59.36 cr | ₹53.91 cr | 10.1% | 9.1% | ₹5.91 | — | — |
| TTM (last 4 quarters) | ₹2,851 cr | ₹311 cr | ₹229 cr | 10.9% | 8.0% | ₹25.05 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
AARTIDRUGS quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
AARTI DRUGS LTD. quarterly income statement| Particulars | Q2 FY272026-09-30 | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹826 cr | ₹703 cr | ₹720 cr | ₹602 cr | ₹653 cr | ₹591 cr |
|---|
| Total expenses | ₹720 cr | ₹623 cr | ₹643 cr | ₹565 cr | ₹585 cr | ₹531 cr |
|---|
| Gross profit | — | ₹275 cr | ₹270 cr | ₹215 cr | ₹245 cr | ₹217 cr |
|---|
| Operating profit (EBIT) | ₹116 cr | ₹79.74 cr | ₹77.76 cr | ₹37.09 cr | ₹68.03 cr | ₹59.36 cr |
|---|
| Operating margin | 14.1% | 11.3% | 10.8% | 6.2% | 10.4% | 10.1% |
|---|
| Interest cost | ₹9.63 cr | ₹9.22 cr | ₹8.16 cr | ₹9.29 cr | ₹7.7 cr | ₹8.56 cr |
|---|
| Profit before tax | ₹109 cr | ₹69.24 cr | ₹70.36 cr | ₹29.02 cr | ₹60.41 cr | ₹51.11 cr |
|---|
| Tax expense | ₹26.51 cr | ₹19.11 cr | ₹15.1 cr | -₹11.53 cr | ₹15.25 cr | -₹2.86 cr |
|---|
| Effective tax rate | 24.3% | 27.6% | 21.5% | -39.7% | 25.2% | -5.6% |
|---|
| Net profit (PAT) | ₹82.77 cr | ₹50.17 cr | ₹55.19 cr | ₹40.54 cr | ₹45.28 cr | ₹53.91 cr |
|---|
| Net profit margin | 10.0% | 7.1% | 7.7% | 6.7% | 6.9% | 9.1% |
|---|
| Basic EPS | ₹9.07 | ₹5.49 | ₹6.05 | ₹4.44 | ₹4.95 | ₹5.91 |
|---|
| Diluted EPS | — | ₹5.49 | ₹6.05 | ₹4.44 | ₹4.95 | ₹5.91 |
|---|
AARTIDRUGS results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q2 FY27 | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +26.6% | +19.0% | — | — | — | — |
|---|
| Revenue QoQ | +17.6% | -2.4% | +19.7% | -7.8% | +10.5% | — |
|---|
| Operating profit YoY | +71.0% | +34.3% | — | — | — | — |
|---|
| Operating profit QoQ | +45.9% | +2.5% | +109.7% | -45.5% | +14.6% | — |
|---|
| Net profit YoY | +82.8% | -6.9% | — | — | — | — |
|---|
| Net profit QoQ | +65.0% | -9.1% | +36.1% | -10.5% | -16.0% | — |
|---|
| EPS YoY | +83.2% | -7.1% | — | — | — | — |
|---|
| EPS QoQ | +65.2% | -9.3% | +36.3% | -10.3% | -16.2% | — |
|---|
AARTIDRUGS annual results history
Full-year performance for AARTI DRUGS LTD., useful for reading each quarter in context.
AARTI DRUGS LTD. annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹2,521 cr | ₹2,369 cr | ₹2,509 cr | ₹2,706 cr |
|---|
| Total expenses | ₹2,268 cr | ₹2,126 cr | ₹2,231 cr | ₹2,439 cr |
|---|
| Gross profit | ₹506 cr | ₹479 cr | ₹851 cr | ₹483 cr |
|---|
| Operating profit (EBIT) | ₹253 cr | ₹243 cr | ₹278 cr | ₹266 cr |
|---|
| Operating margin | 10.0% | 10.3% | 11.1% | 9.8% |
|---|
| Interest cost | ₹33.71 cr | ₹35.87 cr | ₹33.52 cr | ₹33.29 cr |
|---|
| Profit before tax | ₹211 cr | ₹212 cr | ₹236 cr | ₹224 cr |
|---|
| Tax expense | ₹15.96 cr | ₹43.67 cr | ₹63.94 cr | ₹57.82 cr |
|---|
| Effective tax rate | 7.6% | 20.6% | 27.1% | 25.8% |
|---|
| Net profit (PAT) | ₹195 cr | ₹168 cr | ₹171 cr | ₹166 cr |
|---|
| Net profit margin | 7.7% | 7.1% | 6.8% | 6.1% |
|---|
| Basic EPS | ₹21.36 | ₹18.35 | ₹18.56 | ₹17.97 |
|---|
| Diluted EPS | ₹21.36 | ₹18.35 | ₹18.56 | ₹17.97 |
|---|
Revenue trend and demand read-through
Topline for Q2 FY27 came in at ₹826 cr against ₹653 cr in Q2 FY26, and ₹703 cr in the preceding Q1 FY27 quarter.
On a sequential basis revenue grew +17.6%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹720 cr, or 87.1% of revenue, with operating profit grew +71.0% year on year.
Margins, tax and profitability
Net profit of ₹82.77 cr works out to a net margin of 10.0% compared with 6.9% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, AARTI DRUGS LTD. reported profit before tax of ₹109 cr, a tax charge of ₹26.51 cr (effective rate 24.3%), interest cost of ₹9.63 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹50.17 cr in Q1 FY27 to ₹82.77 cr in Q2 FY27, a change of +65.0%.
Trailing twelve months and annual context
Across the trailing four quarters AARTI DRUGS LTD. has generated revenue of ₹2,851 cr and net profit of ₹229 cr, a trailing net margin of 8.0%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹2,521 cr with net profit of ₹195 cr and EPS of ₹21.36, versus the prior year where revenue grew +6.4% and profit grew +15.9%.
What to watch in the next AARTIDRUGS quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
No next results date is available in the board-meeting calendar. Statement figures update when Yahoo Finance makes them available; this is not an immediate exchange-filing feed.
Financial figures here are supplied through Yahoo Finance fundamentals and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
AARTIDRUGS results coverage
No results report published for AARTIDRUGS yet — our desk covers each quarter within minutes of the filing.
AARTIDRUGS results date history
AARTI DRUGS LTD. past board meeting dates for financial results| Board meeting date | Purpose | Details |
|---|
| 3 Nov 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
More on AARTIDRUGS
AARTIDRUGS quarterly results FAQs
What were AARTI DRUGS LTD. (AARTIDRUGS) Q2 FY27 results?
In Q2 FY27 (quarter ended 30 Sept 2026), AARTI DRUGS LTD. reported revenue of ₹826 cr and net profit of ₹82.77 cr, a change of +82.8% year on year on +26.6% revenue growth. EPS stood at ₹9.07.
What is AARTIDRUGS profit margin in Q2 FY27?
AARTI DRUGS LTD. posted a net profit margin of 10.0% and an operating margin of 14.1% in Q2 FY27. On a trailing twelve-month basis, revenue is ₹2,851 cr and net profit ₹229 cr.
Did AARTIDRUGS results beat the previous quarter?
AARTI DRUGS LTD. net profit changed +65.0% quarter on quarter, from ₹50.17 cr in Q1 FY27 to ₹82.77 cr in Q2 FY27.
When are AARTI DRUGS LTD. (AARTIDRUGS) quarterly results?
AARTI DRUGS LTD. has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see AARTIDRUGS latest quarterly results?
Results coverage for AARTIDRUGS will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the AARTIDRUGS stock page.
What is AARTI DRUGS LTD. annual revenue and profit?
For FY26, AARTI DRUGS LTD. reported full-year revenue of ₹2,521 cr and net profit of ₹195 cr, with EPS of ₹21.36.
How many quarterly results has AARTIDRUGS declared recently?
AARTIDRUGS has held 1 recent board meetings for financial results, the last on 3 Nov 2026.
Results dates: NSE board-meeting calendar. Financial figures: Yahoo Finance fundamentals, not a direct exchange filing feed. Last successful data fetch 4 Nov 2026. Figures can be delayed; results change only when the provider publishes them. For information only, not investment advice.
